Diphtheria - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diphtheria - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Diphtheria - Pipeline Review, H2 2015', provides an overview of the Diphtheria's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diphtheria
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diphtheria and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diphtheria pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diphtheria
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diphtheria Overview 10
Therapeutics Development 11
Pipeline Products for Diphtheria - Overview 11
Pipeline Products for Diphtheria - Comparative Analysis 12
Diphtheria - Therapeutics under Development by Companies 13
Diphtheria - Therapeutics under Investigation by Universities/Institutes 15
Diphtheria - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diphtheria - Products under Development by Companies 19
Diphtheria - Products under Investigation by Universities/Institutes 21
Diphtheria - Companies Involved in Therapeutics Development 22
Beijing Minhai Biotechnology Co., Ltd 22
Biological E. Limited 23
Boryung Pharmaceutical Co., Ltd. 24
Daiichi Sankyo Company, Limited 25
GlaxoSmithKline Plc 26
Green Cross Corporation 27
Indian Immunologicals Limited 28
LG Life Science LTD. 29
Panacea Biotec Limited 30
Prometheon Pharma, LLC 31
Sanofi 32
Sanofi Pasteur SA 33
Serum Institute of India Limited 34
Sinovac Biotech Ltd. 35
Zydus Cadila Healthcare Limited 36
Diphtheria - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(diphtheria + pertussis (wholl cell) + tetanus + hepatitis B + Haemophilus influenza [serotype B]) (pentavalent) vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B] + polio) vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B]) vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(diphtheria + tetanus + pertussis (whole cell) + Haemophilus influenzae [serotype B] + polio) (pentavalent) vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + Haemophilus influenzae [serotype B] + polio) (hexavalent) vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + poliomyelitis + Haemophilus influenzae [serotype B]) (hexavalent) vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
(diphtheria + tetanus + pertussis (whole cell)) vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(diphtheria + tetanus + pertussis (whole-cell) + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C]) (7-valent) vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(diphtheria + tetanus + pertussis (whole-cell)) vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
(diphtheria + tetanus) vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
(diphtheria + tetanus+ pertussis (whole cell) + hepatitis B + Haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
diphtheria vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
diphtheria vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
GC-1107 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
GC-3111A - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PR-5I - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
VN-0103 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
VN-0105 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Diphtheria - Recent Pipeline Updates 76
Diphtheria - Dormant Projects 77
Diphtheria - Discontinued Products 78
Diphtheria - Product Development Milestones 79
Featured News & Press Releases 79
Nov 14, 2014: Biological E to Supply Pentavalent Vaccine For Telangana State Immunization Program 79
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 79
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 80
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 80
Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 81
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 81
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 82
Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults. 83
Aug 28, 2000: Aventis Pasteur Inc. Gets FDA Approval to Expand Use of Tripedia to Fifth Consecutive Dose in Diphtheria/Tetanus/Pertussis Immunization Series. 83
Jul 13, 1995: Connaught Laboratories, Inc. Applies to FDA for Licensing of Tripedia for Infant Use 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables

Number of Products under Development for Diphtheria, H2 2015 11
Number of Products under Development for Diphtheria - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 22
Diphtheria - Pipeline by Biological E. Limited, H2 2015 23
Diphtheria - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015 24
Diphtheria - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 25
Diphtheria - Pipeline by GlaxoSmithKline Plc, H2 2015 26
Diphtheria - Pipeline by Green Cross Corporation, H2 2015 27
Diphtheria - Pipeline by Indian Immunologicals Limited, H2 2015 28
Diphtheria - Pipeline by LG Life Science LTD., H2 2015 29
Diphtheria - Pipeline by Panacea Biotec Limited, H2 2015 30
Diphtheria - Pipeline by Prometheon Pharma, LLC, H2 2015 31
Diphtheria - Pipeline by Sanofi, H2 2015 32
Diphtheria - Pipeline by Sanofi Pasteur SA, H2 2015 33
Diphtheria - Pipeline by Serum Institute of India Limited, H2 2015 34
Diphtheria - Pipeline by Sinovac Biotech Ltd., H2 2015 35
Diphtheria - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 36
Assessment by Monotherapy Products, H2 2015 37
Assessment by Combination Products, H2 2015 38
Number of Products by Stage and Target, H2 2015 40
Number of Products by Stage and Route of Administration, H2 2015 42
Number of Products by Stage and Molecule Type, H2 2015 44
Diphtheria Therapeutics - Recent Pipeline Updates, H2 2015 76
Diphtheria - Dormant Projects, H2 2015 77
Diphtheria - Discontinued Products, H2 2015 78